Datroway, a specifically engineered TROP2-directed antibody drug conjugate or ADC, was discovered by Daiichi Sankyo, and is being jointly developed and commercialised by AstraZeneca and Daiichi ...

Datroway is a targeted trophoblast cell surface antigen 2 (TROP2)-directed DXd antibody drug conjugate (ADC), developed using Daiichi Sankyo's DXd ADC Technology.

First approval in the U.S. for Daiichi Sankyo and AstraZeneca’ s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except in Japan ...

The original said Datroway was AstraZeneca's product without mention of Daiichi Sankyo both in the headline and the body of article. (END) Dow Jones Newswires June 24, 2025 02:33 ET (06:33 GMT) ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and Datroway are forecast to pull in $13.9bn and $5.3bn in sales in 2030, respectively, according to GlobalData ...

Daiichi Sankyo recognizes Datroway’s sales in the U.S. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR).